Reading ALLR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALLR free→Reading ALLR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALLR free→QuarterlyIQ Insights · ALLR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 5.02(e) As previously disclosed, effective June 1, 2024, Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Management Services Agreement (the “Original MSA”) with Ljungaskog Consulting AB, a Swedish limited liability company (the “Consultant”), owned and managed by Thomas H. Jensen (“Mr. Jensen”), the Company’…
Results of Operations and Financial Condition. On March 31, 2026, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…
Entry into a Material Definitive Agreement. On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase agreement (the “ Purchase Agreement ”) with Streeterville Capital, LLC, a Utah limited liability company (“ Lender ”), pursuant to which the Company issued and sold to the Lender (i) a promissory note in the original principal amount of $10,930,000 (the “ A-1 Note ,” together with any notes issued pursuant to the Note Exchange (as def…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Entry into a Material Definitive Agreement. Equity Line of Credit Common Stock Purchase Agreement On January 28, 2026, Allarity Therapeutics, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) with Tumim Stone Capital LLC, a Delaware limited liability company (the “ Investor ”). Pursuant to the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Investor up to the lesser of: (a) $6,000,000 of newly issued shares…
Unregistered Sales of Equity Securities. As previously disclosed, on September 22, 2025, Allarity Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated September 22, 2025 (the “Purchase Agreement”) with a certain accredited investor named therein (the “Investor”), pursuant to which the Company sold 1,562,500 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and/or Pre-Funded Warrants to the Investor, in a private placement…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 5.02(e) Ervin December Employment Agreement As previously disclosed, in connection with the appointment of Mr. Jeffrey S. Ervin as Chief Financial Officer of Allarity Therapeutics, Inc. (the “Company”), the Company and Mr. Ervin entered into an employment agreement dated July 1, 2025 (the “July Employment Agreement”), pursuant to which Mr. Erv…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 22, 2025, Allarity Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain accredited investor named therein (the “Investor”), pursuant to which the Company agreed to sell the Shares and/or Pre-Funded Warrants (as defined below) to the Investor, in a private placement transaction (the “Private Placement”). The initial closing of the Private P…
Unregistered Sales of Equity Securities. The disclosure regarding the Shares and/or Pre-Funded Warrants to be sold and issued under the Purchase Agreement set forth under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer On June 30, 2025, Alexander Epshinsky, Chief Financial Officer of Allarity Therapeutics, Inc. (the “Company”), resigned from the Company. The resignation was not the result of any disagreement with the Company regarding its operations, policies or practices, including accounting principles, practices or disclosu…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On June 5, 2025, the Board of Directors (the “ Board ”) of Allarity Therapeutics, Inc. (the “ Company ”) received the resignation of Joseph W. Vazzano as director of the Company, effective June 30, 2025. On June 10, 2025, the Board appointed Mr. Jesper Høiland as a director of the Company, effective as of June 30, 2025. Mr. Høiland’s term will exp…
Other Events. On June 4, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing a research collaboration with Indiana Biosciences Research Institute to further advance the understanding of stenoparib’s unique mechanism of action. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Results of Operations and Financial Condition. On May 9, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 16, 2025, in order to achieve a more equal balance of membership among the classes of directors, the Board of Directors (the “Board”) of Allarity Therapeutics, Inc. (the “Company”) determined to move Thomas H. Jensen from Class I, with a term expiring at the 2026 annual meeting of stockholders, to Class III, with a term expiring at the 202…
Results of Operations and Financial Condition. On March 31, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024 and forward-looking statements relating to its first quarter of 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the…
Other Events. On March 3, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing that its board of directors has approved a share repurchase program (the “Share Repurchase Program”), with authorization to repurchase up to $5 million of the Company’s outstanding shares of common stock. The Company intends to fund any repurchases under the Share Repurchase Program with available cash. The timing and amount of any shares repurchased will be determined based on the Co…
Other Events. On February 26, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing the dismissal of the securities class action lawsuit previously referenced in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2024. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Other Events. On February 24, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing a new Phase 2 protocol to advance stenoparib towards FDA approval in advanced ovarian cancer patients. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Other Events. Settlement in Principle As previously disclosed, Allarity Therapeutics, Inc. (the “Company”) has been the subject of an investigation (the “Investigation”) by the Securities and Exchange Commission (the “SEC”) which relates to the Company’s disclosures regarding meetings with the United States Food and Drug Administration (the “FDA”) regarding the Company’s New Drug Application ("NDA") for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021. The Company has reache…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.